Association of alkaline phosphatase with clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302

被引：0
|
作者：
Mainwaring, P. [1 ]
Yu, E. Y. [2 ]
Londhe, A. [3 ]
Van Poppel, H. [4 ]
Rathkopf, D. E. [5 ,6 ]
Smith, M. R. [7 ,8 ]
Souza, P. [9 ]
Griffin, T. W. [10 ]
Ryan, C. J. [11 ]
机构：
[1] Hematol & Oncol Clin Australia, Brisbane, Qld, Australia
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Janssen Res & Dev LLC, Raritan, NJ USA
[4] Katholieke Univ Leuven Hosp, Louvain, Belgium
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] Weill Cornell Med Coll, New York, NY USA
[7] Harvard Univ, Sch Med, Boston, MA USA
[8] Massachusetts Gen Hosp, Boston, MA 02114 USA
[9] Univ Western Sydney, Sch Med, Sydney, NSW, Australia
[10] Janssen Res & Dev, Los Angeles, CA USA
[11] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
BJU INTERNATIONAL | 2014年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
41
引用
收藏
页码：21 / 21
页数：1
相关论文
共 50 条
  • [41] Enzalutamide in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
    Pu, Yeong-Shiau
    Ahn, Hanjong
    Han, Weiqing
    Huang, Shu-Pin
    Wu, Hsi-Chin
    Ma, Lulin
    Yamada, Shunsuke
    Suga, Kazutaka
    Xie, Li-Ping
    ADVANCES IN THERAPY, 2022, 39 (06) : 2641 - 2656
  • [42] Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer
    Dong, Baijun
    Fan, Liancheng
    Wang, Yanqing
    Chi, Chenfei
    Ma, Xiaowei
    Wang, Rui
    Cai, Wen
    Shao, Xiaoguang
    Pan, Jiahua
    Zhu, Yinjie
    Xun Shangguan
    Xin, Zhixiang
    Hu, Jianian
    Xie, Shaowei
    Kang, Xiaonan
    Zhou, Lixin
    Xue, Wei
    PROSTATE, 2017, 77 (13): : 1373 - 1380
  • [43] The association between antibiotics administration and outcomes in men with chemotherapy-naive metastatic castration-resistant prostate cancer: Secondary analysis of two randomized clinical trials
    Ni, Xudong
    Wei, Yu
    Ye, Ding-Wei
    Zhu, Yao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
    Bracarda, S.
    Sisani, M.
    Rossi, M.
    Galli, L.
    Hamzaj, A.
    Scali, S.
    De Angelis, V.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naive metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study
    Poon, Darren M. C.
    Chan, Kuen
    Lee, Siu H.
    Chan, Tim W.
    Sze, Henry
    Lee, Eric K. C.
    Lam, Daisy
    Chan, Michelle F. T.
    PROSTATE INTERNATIONAL, 2018, 6 (01) : 24 - 30
  • [46] The PREVAIL trial of enzalutamide (ENZA) in men with chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC): subgroup analysis of Asian patients
    Kim, Choung-soo
    Choi, Young Deuk
    Lee, Sangchul
    Lee, Hyun Moo
    Ueda, Takeshi
    Yonese, Junji
    Fukagai, Takashi
    Mansbach, Harry
    Theeuwes, Ad
    Beer, Tomasz M.
    Tombal, Bertrand
    Kimura, Go
    BJU INTERNATIONAL, 2015, 116 : 14 - 14
  • [47] Subgroup analysis of Japanese men in the PREVAIL trial of enzalutamide (ENZA) in men with chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC)
    Kimura, G.
    Yonese, J.
    Fukagai, T.
    Kamba, T.
    Nishimura, K.
    Nozawa, M.
    Parli, T.
    Theeuwes, A.
    Beer, T. M.
    Tombal, B.
    Ueda, T.
    ANNALS OF ONCOLOGY, 2015, 26 : 74 - 74
  • [48] Overall survival by race in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
    McNamara, Megan Ann
    George, Daniel J.
    Ramaswamy, Krishnan
    Lechpammer, Stanislav
    Mardekian, Jack
    Schultz, Neil M.
    Wang, Li
    Baser, Onur
    Huang, Ahong
    Freedland, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [49] Subgroup analysis of Asian men in the PREVAIL trial of enzalutamide (ENZA) in men with chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC)
    Kim, C. -S.
    Choi, Y. D.
    Lee, S. E.
    Lee, H. M.
    Ueda, T.
    Yonese, J.
    Fukagai, T.
    Chiong, E.
    Lau, W.
    Abhyankar, S.
    Theeuwes, A.
    Tombal, B.
    Beer, T. M.
    Kimura, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 73 - 73
  • [50] THE IMPACT OF ABIRATERONE ACETATE (AA) THERAPY ON PATIENT-REPORTED PAIN AND FUNCTIONAL STATUS IN CHEMOTHERAPY-NAIVE PATIENTS WITH PROGRESSIVE, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Basch, E.
    Ryan, C. J.
    Kheoh, T.
    Fizazi, K.
    Logothetis, C. J.
    Rathkopf, D. E.
    Smith, M. R.
    Mainwaring, P. N.
    Hao, Y.
    Griffin, T.
    Li, S.
    Meyers, M.
    Molina, A.
    Cleeland, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 295 - 295
12345